But I think we have great teams within Biogen and we are able to really dissect ... we've seen a robust reduction of the MAPT mRNA or tau protein levels in brain regions where BIIB080 was detected.

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Meanwhile, Biogen also reported data from a long-term ... and also cut plasma levels of a biomarker protein called p-tau181 at week 128, according to a presentation of the data at the ...

Biogen has made a further push into RNA-based ... which is used as a template for protein synthesis in cells – is transformed into a mature form. As its name suggests, splicing involves snipping ...

The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...

With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, ...

People who are 75 and older will compose 10% of the total population in the U.S. by 2030, representing a 7.5% increase from ...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing ...

Soon after her diagnosis, Green learned about a clinical trial at Mass General for an experimental drug — QALSODY® (tofersen), which is made by Biogen in Cambridge, Massachusetts. The ...

New research warns that blood tests for Alzheimer’s disease may be unreliable, particularly for Black patients. A recent ...